RIP tanezumab? Eli Lilly, Pfizer spotlight alarming safety data for NGF pain drug in PhIII
Nearly a decade after the anti-NGF class of pain drugs was crushed by safety issues and then began a long, agonizingly slow return to late-stage testing, it may all be over soon. Pfizer and Eli Lilly posted a set of longterm outcomes from a Phase III study of tanezumab, and once they got a glimpse of the data analysts immediately started to pen last rites for the drug.
A rival therapy from Regeneron and Teva isn’t being given good odds of survival.
There were mixed efficacy results for the Pfizer/Lilly program, with only the high dose achieving a statistically significant improvement for pain and physical function over NSAIDS. And the pain data were alarming, reflecting earlier concerns spotlighted by researchers.
Basic subscription required
Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.